Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trilomer-PTK7 conjugate
- Development stage
- Preclinical
- Lead developer
- Trilo Therapeutics
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
01
Overview
Trilomer-PTK7 conjugate is a peptide-drug conjugate (PDC) developed by Trilo Therapeutics for the treatment of PTK7-expressing cancers. It utilizes the proprietary Trilomer® platform, which consists of mirror-image D-amino acid cyclic peptides. These peptides are designed as bivalent or biparatopic binders that are highly resistant to protease degradation and exhibit low immunogenicity. The conjugate functions by binding to Protein Tyrosine Kinase 7 (PTK7) on the surface of cancer cells and delivering a conjugated cytotoxic or radionuclide payload to induce cell death. This ADC-like approach leverages the stability of D-peptides to improve the therapeutic index of the payload. The drug is currently in preclinical development.
- Other names
- Trilomer-PTK7Trilomer-PTK-7Trilomer-PTK 7
02
Targets
PTK7 (Protein tyrosine kinase 7)
Beyond the preview
Go deeper on Trilomer-PTK7 conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trilomer-PTK7 conjugate.